Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) in Patients With Head and Neck Tumor
Phase 1
Completed
- Conditions
- Head and Neck Tumor
- Registration Number
- NCT00406289
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
This study will evaluate the feasibility of higher and prolonged dose escalation concentrated in the intra-tumoral regions which are FDG-avid after two weeks of radiotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Head and neck tumor
- Aged > 18 years
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Tumor recurrences
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie FDG-avid tumor regions in head and neck cancer during adaptive radiotherapy?
How does BG-IMRT compare to standard IMRT in treating squamous cell carcinoma of the head and neck?
Which biomarkers correlate with FDG-PET response prediction in NCT00406289 head and neck tumor trials?
What adverse events are associated with prolonged dose escalation in FDG-avid regions using BG-IMRT?
Are there combination therapies with BG-IMRT for head and neck tumors, such as EGFR inhibitors or immunotherapy?
Trial Locations
- Locations (1)
University Hospital Ghent
🇧🇪Ghent, Belgium